Financial results for the first half of 2011

• Strong validation for Innate Pharma’s two most advanced programs
  
• Controlled burn rate and strong cash position

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces today its financial results for the first half of 2011.

Innate Pharma has made significant progress in its corporate development and its innovative immunotherapy pipeline over 2011. With now two collaborations with major pharma partners, Novo Nordisk A/S and Bristol-Myers Squibb, Innate Pharma has achieved strong validation for the key concepts of its science and its unique positioning in innate immunity.